Editas Medicine, Inc. - Common Stock (EDIT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
EDIT on Nasdaq
Shares outstanding
82,773,190
Price per share
$2.06
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
49,820,281
Total reported value
$102,226,398
% of total 13F portfolios
0%
Share change
+7,124,867
Value change
+$13,644,443
Number of holders
189
Price from insider filings
$2.06
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Editas Medicine, Inc. - Common Stock (EDIT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 7.9% $10,527,922 6,539,082 BlackRock, Inc. 31 Mar 2025

As of 31 Dec 2025, 189 institutional investors reported holding 49,820,281 shares of Editas Medicine, Inc. - Common Stock (EDIT). This represents 60% of the company’s total 82,773,190 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Editas Medicine, Inc. - Common Stock (EDIT) together control 52% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 11% 9,347,114 +17% 0% $19,161,582
VANGUARD GROUP INC 9.9% 8,208,068 +18% 0% $16,826,539
RENAISSANCE TECHNOLOGIES LLC 3.7% 3,039,778 +138% 0.01% $6,231,545
GEODE CAPITAL MANAGEMENT, LLC 2.8% 2,284,740 +12% 0% $4,684,759
Nuveen, LLC 2.4% 1,976,900 -5.5% 0% $4,052,645
STATE STREET CORP 2.4% 1,974,931 +2.6% 0% $4,048,609
TWO SIGMA INVESTMENTS, LP 2% 1,632,584 +3.1% 0% $3,346,797
TWO SIGMA ADVISERS, LP 1.5% 1,224,100 +1.6% 0% $2,509,405
RAYMOND JAMES FINANCIAL INC 1.4% 1,184,670 +623% 0% $2,428,573
JANE STREET GROUP, LLC 1.4% 1,176,580 +128% 0% $2,411,989
D. E. Shaw & Co., Inc. 1.3% 1,109,590 +855% 0% $2,274,659
GOLDMAN SACHS GROUP INC 1.1% 881,960 +92% 0% $1,808,018
JACOBS LEVY EQUITY MANAGEMENT, INC 1% 827,140 +3.4% 0.01% $1,695,637
CITADEL ADVISORS LLC 0.99% 820,993 +127% 0% $1,683,035
UBS Group AG 0.98% 809,342 +92% 0% $1,659,151
ACADIAN ASSET MANAGEMENT LLC 0.97% 799,847 +124% 0% $1,635,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.96% 794,671 +1.9% 0% $1,629,076
JPMORGAN CHASE & CO 0.95% 783,104 -4.6% 0% $1,605,363
Point72 Asset Management, L.P. 0.89% 733,483 0% $1,503,640
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.85% 704,662 -12% 0% $1,444,557
MORGAN STANLEY 0.82% 678,913 -38% 0% $1,391,772
NORTHERN TRUST CORP 0.8% 662,459 -1.1% 0% $1,358,041
AQR CAPITAL MANAGEMENT LLC 0.78% 644,197 -6.3% 0% $1,320,604
GSA CAPITAL PARTNERS LLP 0.69% 568,809 0.1% $1,166,000
KENNEDY CAPITAL MANAGEMENT LLC 0.68% 562,140 -0.62% 0.02% $1,152,387

Institutional Holders of Editas Medicine, Inc. - Common Stock (EDIT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 49,820,281 $102,226,398 +$13,644,443 $2.05 189
2025 Q3 43,074,438 $149,420,142 +$7,918,480 $3.47 192
2025 Q2 41,335,195 $90,959,890 -$2,651,384 $2.20 190
2025 Q1 44,017,732 $51,056,496 -$8,643,822 $1.16 189
2024 Q4 51,050,083 $64,829,211 -$26,980,305 $1.27 199
2024 Q3 55,026,910 $187,727,875 -$7,609,494 $3.41 223
2024 Q2 56,388,612 $263,332,828 -$55,730,958 $4.67 229
2024 Q1 67,934,083 $503,995,838 +$62,859,602 $7.42 221
2023 Q4 58,810,431 $595,736,469 -$24,830,057 $10.13 222
2023 Q3 61,671,930 $481,001,719 -$15,318,112 $7.80 220
2023 Q2 62,806,728 $516,820,804 +$83,105,555 $8.23 234
2023 Q1 52,966,709 $383,993,662 -$13,671,500 $7.25 231
2022 Q4 54,069,648 $479,580,650 +$43,275,611 $8.87 245
2022 Q3 48,268,099 $590,813,665 +$8,782,042 $12.24 243
2022 Q2 47,470,750 $561,353,937 +$5,825,446 $11.83 235
2022 Q1 45,377,308 $862,213,005 -$137,494,973 $19.02 239
2021 Q4 50,935,353 $1,354,989,098 -$58,058,784 $26.55 288
2021 Q3 51,686,909 $2,124,275,170 -$9,901,736 $41.08 307
2021 Q2 52,115,846 $2,960,972,143 -$42,349,447 $56.64 309
2021 Q1 53,112,966 $2,230,651,006 -$37,048,235 $42.00 296
2020 Q4 52,925,101 $3,710,809,621 -$146,422,850 $70.11 303
2020 Q3 55,153,663 $1,547,459,830 +$15,957,942 $28.06 233
2020 Q2 54,180,331 $1,601,145,803 +$263,790,568 $29.58 225
2020 Q1 45,615,983 $904,572,484 -$9,115,772 $19.83 186
2019 Q4 45,765,436 $1,355,110,145 +$25,771,039 $29.61 221
2019 Q3 44,998,047 $1,024,181,318 +$117,742,869 $22.74 180
2019 Q2 39,755,008 $983,423,600 +$65,857,366 $24.74 187
2019 Q1 37,451,919 $915,659,367 +$73,756,065 $24.45 194
2018 Q4 34,476,789 $784,057,800 +$24,196,841 $22.75 187
2018 Q3 33,225,759 $1,057,110,921 +$32,891,792 $31.82 192
2018 Q2 32,137,091 $1,150,684,888 +$38,224,646 $35.83 208
2018 Q1 31,152,906 $1,032,691,989 +$25,997,611 $33.15 192
2017 Q4 30,385,119 $934,032,943 +$80,818,257 $30.73 146
2017 Q3 27,385,418 $657,479,359 +$43,906,788 $24.01 115
2017 Q2 25,837,623 $433,614,752 +$21,311,417 $16.78 107
2017 Q1 27,537,538 $614,414,843 +$120,573,551 $22.32 99
2016 Q4 23,494,260 $381,310,290 +$21,340,854 $16.23 84
2016 Q3 22,215,862 $299,468,288 +$9,006,129 $13.48 71
2016 Q2 17,634,311 $429,193,163 -$15,061,641 $24.40 64
2016 Q1 18,151,358 $625,254,000 +$464,066,000 $34.54 48